



10 September 2025

dorsaVi signs multi-year sales agreement with leading US Physical Therapy Network

Key Highlights:

- **dorsaVi has signed a five-year sales agreement deal with U.S. based Select Medical to offer purchasing options for its FDA approved products across the company's national network of over 1,900 outpatient physical therapy centres.**
- **dorsaVi has worked with Select Medical for 18 months in a development pilot, to ensure the technology met therapists' needs.**
- **Development pilot included the collection of accurate and useful clinical data to assist in the rehabilitation of injured athletes and return to play assessments.**
- **The dorsaVi product suite will be available to purchase beginning in September 2025.**

Melbourne, Australia, 10 September 2025: dorsaVi (ASX:DVL) (dorsaVi or the Company) is pleased to announce that it has signed a new five-year sales agreement with US based Select Medical to offer purchasing options for its products across Select Medicals national network of 1,900+ outpatient physical therapy centres. There is no contractual obligation to procure products, including no quantity guarantees.

As part of the clinical evaluation of dorsaVi products, the two entities underwent an 18-month development pilot to ensure the technology met therapists' needs, including the collection of accurate and useful clinical data to assist in the rehabilitation of injured athletes and return to play assessments.

Andrew Ronchi, CEO dorsaVi Ltd, said:

"We are delighted to have this opportunity to work with Select Medical. They are one of the largest providers of outpatient rehabilitation clinics in the United States, and we are thrilled that our technology will have an opportunity to play a pivotal role in patient assessment and rehabilitation."

This release has been authorised for lodgement by the Company's Board of Directors.

- ENDS -

For further information about dorsaVi, please contact:

Gernot Abl Chairman +61 419 802 653 Email: ga@dorsaVi.com	Andrew Ronchi CEO dorsaVi Ltd +61 417 882 267 Email: ar@dorsaVi.com
--	--

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.

dorsaVi's Products

Video AI:

The Video AI product provides rapid movement assessment and instant reporting. There are no sensors required for this application and the iPad camera is able to track the limb movements and dorsaVi's proprietary Video AI algorithm tracks each limb, calculates and the angular change between limbs and reports this data instantly to a clinician, elite performance manager or safety professional.

Sensor based:

For clinician's wanting the most accurate version of the product, there is the sensor based Athletic Movement Index (AMI) product which includes dorsaVi's FDA cleared sensor application which correlates to the Gold Standard Vicon system, to within 1-2 degrees, providing the validation and confidence surgeons and physicians want in their Return to Sport assessments.

The AMI assessment takes the athlete through a complex set of pre-determined and graded exercise tasks. The automated report compares the right side to left side, provides an overall movement score and allows the clinician to review each repetition of the test regime, with automated 'Key Clinical Takeaways' and a guide to corrective actions.

dorsaVi's Market Focus

Workplace:

dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Boeing, Monash Health, Coles, Woolworths, Toll, Toyota, Orora, Mineral Resources and BHP Billiton.

Clinical:

dorsaVi is transforming the management of patients with its clinical solutions (ViMove+) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refer to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsaVi.com